Asymchem Laboratories (Tianjin) Co., Ltd.
002821
Rank in Stocks
#2511
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development... Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.
Share Price
$20.91
Market Cap
$7.57B
Change (1 day)
-8.26%
Change (1 year)
41.25%
Country
CN
Trade Asymchem Laboratories (Tianjin) Co., Ltd. (002821)
Category
Healthcare
Revenue for Asymchem Laboratories (Tianjin) Co., Ltd. (002821)
Revenue in Jun 2026 TTM: $1.06B
According to Asymchem Laboratories (Tianjin) Co., Ltd. latest financial reports the company's current revenue (TTM) is $1.06B. In 2024 the company made a revenue of $795.26M a decrease compared to the revenue in the year 2023 that was $1.11B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Asymchem Laboratories (Tianjin) Co., Ltd. from 2011 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $1.06B | 11.34% |
| 2025 | $953.37M | 19.88% |
| 2024 | $795.26M | -28.06% |
| 2023 | $1.11B | -25.46% |
| 2022 | $1.48B | 103.50% |
| 2021 | $728.79M | 51.78% |
| 2020 | $480.16M | 35.91% |
| 2019 | $353.28M | 32.44% |
| 2018 | $266.75M | 21.96% |
| 2017 | $218.72M | 37.65% |
| 2016 | $158.90M | 24.23% |
| 2015 | $127.91M | 10.62% |
| 2014 | $115.63M | 29.23% |
| 2013 | $89.48M | 31.47% |
| 2012 | $68.06M | 5.76% |
| 2011 | $64.35M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 1,089.29% |
US
|
|
| $2.23B | 109.89% |
US
|
|
| $15.74B | 1,383.22% |
AU
|
|
| $10.11B | 852.50% |
BE
|
|
| $6.02B | 467.25% |
NL
|
